Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
The study aimed to enroll ninety-four (94) patients/care partners. The time period for enrollment was dependent on the uptake of KESIMPTA in the real-world.
Data collected for the study was obtained directly from the patient/care partner within the web-based database: De-identified data was stored on a secure server and transferred for analysis. Responses from the patient and care partner surveys were pooled for analysis of study endpoints.
Age
18–100
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult aged eighteen (18) years of age or over at the time of the survey
Prescribed KESIMPTA within the prior 12 months and currently self-administering treatment using the Sensoready® pen
MS diagnosis based on 2017 McDonald criteria
Adult aged eighteen (18) years of age or over
Formal or informal care partner of patient with MS prescribed KESIMPTA within the prior 12 months
Is currently administering KESIMPTA using the Sensoready® pen on their patient's behalf
You may not be if
Previously used injection as a part of inclusion in any ofatumumab (OMB) randomized clinical trial
Active Hepatitis B virus (HBV)
Cognitive impairment that would impact their ability to participate in a survey study
Clareo Health | A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indicated for Multiple Sclerosis
